Abstract:Background Traditionally, the purpose of a dose-finding design in cancer is to find the maximum tolerated dose based solely on toxicity. However, for molecularly targeted agents, little toxicity may arise within the therapeutic dose range and the dose-response curves may not be monotonic. This challenges the principle that more is better, which is widely accepted for conventional chemotherapy. Methods We propose three adaptive dose-finding designs for trials evaluating molecularly targeted agents, for which the dose-response curves are unimodal or plateaued. The goal of these designs is to find the optimal biological dose, which is defined as the lowest dose with the highest rate of efficacy while safe. The first proposed design is parametric and assumes a logistic dose-efficacy curve for dose finding, the second design is nonparametric and uses the isotonic regression to identify the optimal biological dose, and the third design has the spirit of a semiparametric' approach by assuming a logistic model only locally around the current dose. Results We conducted extensive simulation studies to investigate the operating characteristics of the proposed designs. Simulation studies show that the nonparametric and semiparametric designs have good operating characteristics for finding the optimal biological dose. Limitations The proposed designs assume a binary endpoint. Extension of the proposed designs to ordinal and time-to-event endpoints is worth further investigation. Conclusion Among the three proposed designs, the nonparametric and semiparametric designs yield consistently good operating characteristics and thus are recommended for practical use. The software to implement these two designs is available for free download at http://odin.mdacc.tmc.edu/similar to yyuan/.

Benchmark Dose Analysis via Nonparametric Regression Modeling

Bayesian Benchmark Dose Analysis

Bayesian Model-Averaged Benchmark Dose Analysis Via Reparameterized Quantal-Response Models

Semi-parametric Benchmark Dose Analysis with Monotone Additive Models

Bayesian benchmark dose risk assessment with mixed‐factor quantal data

A Bayesian Quasi-Likelihood Design for Identifying the Minimum Effective Dose and Maximum Utility Dose in Dose-Ranging Studies

Quantitative Risk Assessment: Developing a Bayesian Approach to Dichotomous Dose-Response Uncertainty

Benchmark dose modeling for epidemiological dose-response assessment using prospective cohort studies

Bayesian Nonparametric Risk Assessment in Developmental Toxicity Studies with Ordinal Responses

Convex Mixture Regression for Quantitative Risk Assessment

Benchmark dose (BMD) modeling: current practice, issues, and challenges

Monotonic Nonparametric Dose Response Model

Bayesian Model Averaging for Benchmark Dose Estimation

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

Benchmark dose modeling for epidemiological dose–response assessment using case‐control studies

Marginalization in nonlinear mixed-effects models with an application to dose-response analysis

Nonparametric Inference on Dose-Response Curves Without the Positivity Condition

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

Dose-Response Curve Estimation: A Semiparametric Mixture Approach

Bayesian dose-response analysis for epidemiological studies with complex uncertainty in dose estimation

Shrinkage priors for isotonic probability vectors and binary data modeling, with applications to dose–response modeling